New hope for rare brain disorder: phase 3 trial launches

NCT ID NCT07498426

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Apr 04, 2026 · Last updated May 23, 2026 · Updated 8 times

Summary

This study tests an experimental drug called NIO752 in 300 people with progressive supranuclear palsy (PSP), a rare brain disease that affects movement and balance. Participants will receive either the drug or a placebo, and later everyone can get the real drug. The goal is to see if NIO752 can slow down the disease and improve daily function.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROGRESSIVE SUPRANUCLEAR PALSY RICHARDSON SYNDROME (PSP-RS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-••••

Locations

CenExcel Rocky Mtn Clin Research
RECRUITING

Englewood, Colorado, 80113, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Mayo Clinic
RECRUITING

Rochester, Minnesota, 55905, United States

Contact Email: •••••@•••••

Contact
Novartis Investigative Site
RECRUITING

Ulm, 89081, Germany

Conditions

Explore the condition pages connected to this study.

PROGRESSIVE SUPRANUCLEAR PALSY RICHARDSON SYNDROME (PSP-RS)